Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | KCNN4 | O15554 | 8/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6559024 | 0.98 | MAPT (0.57) | MAPTKMT2AKCNN4CYP2C19HIF1A | |
| SCHEMBL2308306 | 0.83 | MAPT (0.47) | MAPTKMT2AKCNN4CYP2C19HIF1A | |
| SCHEMBL13447969 | 0.83 | MAPT (0.47) | MAPTKMT2AKCNN4CYP2C19HIF1A | |
| Trifluoroacetic Acid SCHEMBL27504505 | 0.80 | MAPT (0.44) | MAPTKMT2AKCNN4CYP2C19HIF1A | |
| SCHEMBL1852832 | 0.80 | MAPT (0.44) | MAPTKMT2AKCNN4CYP2C19HIF1A | |
| SCHEMBL12893821 | 0.80 | MAPT (0.44) | MAPTKMT2AKCNN4CYP2C19HIF1A | |
| SCHEMBL12233138 | 0.80 | MAPT (0.44) | MAPTKMT2AKCNN4CYP2C19HIF1A | |
| SCHEMBL10120333 | 0.80 | MAPT (0.44) | MAPTKMT2AKCNN4CYP2C19HIF1A | |
| SCHEMBL1852835 | 0.80 | MAPT (0.44) | MAPTKMT2AKCNN4CYP2C19HIF1A | |
| SCHEMBL4565551 | 0.79 | MAPT (0.44) | MAPTKMT2AKCNN4CYP2C19HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1451156-A4 | 4-AMINOQUINOLINE COMPOUNDS | MERCK & CO INC (US) | 2005-05-25 | — | — | EP | claimed |
| EP-1450801-A2 | 2-AMINOQUINOLINE COMPOUNDS | Merck & Co., Inc. (US) | 2004-09-01 | — | — | EP | claimed |
| EP-1451156-A1 | 4-AMINOQUINOLINE COMPOUNDS | Merck & Co., Inc. (US) | 2004-09-01 | — | — | EP | claimed |
| WO-2003045313-A2 | 2-AMINOQUINOLINE COMPOUNDS | MERCK & CO. INC. (US) | 2003-06-05 | — | — | WO | claimed |
| WO-2003045920-A1 | 4-AMINOQUINOLINE COMPOUNDS | MERCK & CO., INC. (US) | 2003-06-05 | — | — | WO | claimed |
| EP-4326270-A1 | DIAGNOSTIC AND TREATMENT OF CANCER USING C-MET INHIBITOR | Apollomics Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| WO-2022226168-A1 | DIAGNOSTIC AND TREATMENT OF CANCER USING C-MET INHIBITOR | APOLLOMICS INC. (US) | 2022-10-27 | — | — | WO | disclosed |
| CN-110372492-B | Method for synthesizing cinacalcet hydrochloride intermediate by using microchannel reactor | 上药康丽（常州）药业有限公司 | 2022-09-20 | — | — | CN | disclosed |
| WO-2020244968-A1 | FUNGICIDAL N-(PYRID-3-YL)CARBOXAMIDES | BASF SE (DE) | 2020-12-10 | — | — | WO | disclosed |
| US-20200317624-A1 | BICYCLIC QUINAZOLINONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2020-10-08 | — | — | US | disclosed |
| EP-3291817-A1 | HETEROARYL-PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2018-03-14 | — | — | EP | disclosed |
| WO-2016179059-A1 | HETEROARYL-PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-11-10 | — | — | WO | disclosed |
| EP-2912021-A1 | AGGRECANASE INHIBITORS | Eli Lilly and Company (US) | 2015-09-02 | — | — | EP | disclosed |
| WO-2014066151-A1 | AGGRECANASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2014-05-01 | — | — | WO | disclosed |
| EP-2635578-A1 | 2-ARYLIMIDAZO[1,2-B]PYRIDAZINE, 2-PHENYLIMIDAZO[1,2-A]PYRIDINE, AND 2-PHENYLIMIDAZO[1,2-A]PYRAZINE DERIVATIVES | Hengrui (USA) Ltd. (US) | 2013-09-11 | — | — | EP | disclosed |
| WO-2012088411-A1 | 2-ARYLIMIDAZO[1,2-B]PYRIDAZINE, 2-PHENYLIMIDAZO[1,2-A]PYRIDINE, AND 2-PHENYLIMIDAZO[1,2-A]PYRAZINE DERIVATIVES | PAMLICO PHARMACEUTICAL INC. (US) | 2012-06-28 | — | — | WO | disclosed |
| WO-2008016676-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INCORPORATED (US) | 2008-02-07 | — | — | WO | disclosed |
| EP-1606268-A1 | HETEROCYCLIC KINASE INHIBITORS | Abbott Laboratories (US) | 2005-12-21 | — | — | EP | disclosed |
| WO-2004076424-A1 | HETEROCYCLIC KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2004-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200317624-A1 | BICYCLIC QUINAZOLINONE DERIVATIVES | BRD4, BICRA, NDUFC2 | MAPT 3475/4885KMT2A 2242/4885KCNN4 560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.